Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases
Condition: Primary Immune Deficiency Intervention: Biological: Newnorm Sponsor: Octapharma Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials